JP2021517133A5 - - Google Patents

Info

Publication number
JP2021517133A5
JP2021517133A5 JP2020547005A JP2020547005A JP2021517133A5 JP 2021517133 A5 JP2021517133 A5 JP 2021517133A5 JP 2020547005 A JP2020547005 A JP 2020547005A JP 2020547005 A JP2020547005 A JP 2020547005A JP 2021517133 A5 JP2021517133 A5 JP 2021517133A5
Authority
JP
Japan
Prior art keywords
optionally substituted
antibody
antigen
here
pharmaceutical composition
Prior art date
Application number
JP2020547005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517133A (ja
JPWO2019173780A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021464 external-priority patent/WO2019173780A2/en
Publication of JP2021517133A publication Critical patent/JP2021517133A/ja
Publication of JP2021517133A5 publication Critical patent/JP2021517133A5/ja
Publication of JPWO2019173780A5 publication Critical patent/JPWO2019173780A5/ja
Pending legal-status Critical Current

Links

JP2020547005A 2018-03-08 2019-03-08 抗ｃｄ２５２抗体、コンジュゲート、および使用方法 Pending JP2021517133A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862640543P 2018-03-08 2018-03-08
US62/640,543 2018-03-08
PCT/US2019/021464 WO2019173780A2 (en) 2018-03-08 2019-03-08 Anti-cd252 antibodies, conjugates, and methods of use

Publications (3)

Publication Number Publication Date
JP2021517133A JP2021517133A (ja) 2021-07-15
JP2021517133A5 true JP2021517133A5 (https=) 2022-03-15
JPWO2019173780A5 JPWO2019173780A5 (https=) 2022-03-15

Family

ID=67846867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020547005A Pending JP2021517133A (ja) 2018-03-08 2019-03-08 抗ｃｄ２５２抗体、コンジュゲート、および使用方法

Country Status (5)

Country Link
US (1) US20210095039A1 (https=)
EP (1) EP3762400A4 (https=)
JP (1) JP2021517133A (https=)
CN (1) CN112154152A (https=)
WO (1) WO2019173780A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004213053C1 (en) * 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8614295B2 (en) * 2009-02-17 2013-12-24 Ucb Pharma S.A. Antibody molecules having specificity for human OX40
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN105377304B (zh) * 2014-03-10 2018-05-15 海德堡医药有限责任公司 鹅膏毒肽衍生物
MX2017011194A (es) * 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD

Similar Documents

Publication Publication Date Title
KR102295190B1 (ko) 아마니타 독소의 유도체 및 세포 결합 분자와의 그것의 결합
JP2024542073A (ja) 抗体薬物結合体のための特異的共役
US11667696B2 (en) Selective reduction of proteins
JP7730836B2 (ja) 抗体薬物複合体の調製方法
US20150147316A1 (en) Cd33 antibodies and use of same to treat cancer
JP2020506176A5 (https=)
JP2017518304A (ja) 抗体−薬物コンジュゲート、それらの製造、及びそれらの治療用途
KR20210024245A (ko) 사이클로덱스트린 및 항체-약물 포합체 제형
TWI660741B (zh) 抗體藥物複合物及其製造方法
JP2022502431A (ja) スルホマレイミドに基づくリンカーおよび対応する複合体
CN119156231A (zh) 提高鹅膏蕈毒素-抗体缀合物的治疗指数的方法
JP2021517133A5 (https=)
EP3441072B1 (en) Activated carbon filtration for purification of benzodiazepine adcs
WO2024088283A1 (zh) 人源化的l1cam抗体药物偶联物
JPWO2019173780A5 (https=)
JP2021511333A5 (https=)
TW202411249A (zh) 抗體－藥物偶聯物的製備方法
HK40010618A (en) Activated carbon filtration for purification of benzodiazepine adcs
HK40010618B (en) Activated carbon filtration for purification of benzodiazepine adcs
JP2025507707A (ja) 新規の抗体薬剤コンジュゲート
IL318911A (en) Humanized antibodies against NECTIN-4 and their drug conjugates
JPWO2019142147A5 (https=)
NZ615308A (en) Antibody-drug conjugates